Ascendis Pharma A/S (ASND) Stock Forecast & Price Target

$119.15

+0.15 (+0.13%)

(As of 09/6/2024 ET)

Ascendis Pharma A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 14 Analyst Ratings

Based on 14 Wall Street analysts who have issued ratings for Ascendis Pharma A/S in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 1 has given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for ASND.

Consensus Price Target

$187.08
57.01% Upside

High Forecast	$264.00
Average Forecast	$187.08
Low Forecast	$140.00

According to the 14 analysts' twelve-month price targets for Ascendis Pharma A/S, the average price target is $187.08. The highest price target for ASND is $264.00, while the lowest price target for ASND is $140.00. The average price target represents a forecasted upside of 57.01% from the current price of $119.15.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$187.08	$179.00	$179.44	$145.20
Forecasted Upside	57.01% Upside	36.65% Upside	36.79% Upside	45.08% Upside

Get Ascendis Pharma A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Ad Timothy Sykes

Tim Sykes’ Urgent Trade Alert: “Make this move now”

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade

ASND Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ASND Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ascendis Pharma A/S Stock vs. The Competition

Type	Ascendis Pharma A/S	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	57.01% Upside	1,207.57% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/5/2024	Oppenheimer 3 of 5 stars		Upgrade	Market Perform ➝ Outperform	$180.00	+50.63%
9/4/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$193.00 ➝ $178.00	+48.95%
9/4/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$174.00 ➝ $165.00	+38.08%
9/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Werber Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$175.00 ➝ $157.00	+31.80%
9/4/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$165.00 ➝ $175.00	+47.83%
9/4/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$277.00 ➝ $264.00	+116.46%
Get the Latest News and Ratings for ASND and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.
9/4/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$173.00 ➝ $170.00	+26.23%
8/26/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/13/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$174.00 ➝ $196.00	+41.50%
8/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$170.00 ➝ $195.00	+49.35%
5/31/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$200.00	+45.51%
5/16/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$116.00 ➝ $140.00	+13.97%
2/8/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$207.00 ➝ $225.00	+61.53%
10/9/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
4/28/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
4/3/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral
11/14/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$168.00 ➝ $148.00	+33.57%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:43 PM ET.

ASND Forecast - Frequently Asked Questions

What is Ascendis Pharma A/S's forecast for 2024?: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Ascendis Pharma A/S is $187.08, with a high forecast of $264.00 and a low forecast of $140.00.
Should I buy or sell Ascendis Pharma A/S stock right now?: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There is currently 1 hold rating, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASND shares.
Does Ascendis Pharma A/S's stock price have much upside?: According to analysts, Ascendis Pharma A/S's stock has a predicted upside of 47.57% based on their 12-month stock forecasts.
Has Ascendis Pharma A/S been upgraded by Wall Street analysts recently?: Over the previous 90 days, Ascendis Pharma A/S's stock had 3 upgrades by analysts.
What analysts cover Ascendis Pharma A/S?: Ascendis Pharma A/S has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, Evercore ISI, Jefferies Financial Group, JPMorgan Chase & Co., Oppenheimer, TD Cowen, The Goldman Sachs Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Ascendis Pharma A/S more than its competitors?: Analysts like Ascendis Pharma A/S more than other "medical" companies. The consensus rating for Ascendis Pharma A/S is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ASND compares to other companies.